Skip to main content

Table 1 Baseline characteristics in all patients, dieters versus nondieters, and users of methotrexate versus nonusers

From: Effects of disease modifying agents and dietary intervention on insulin resistance and dyslipidemia in inflammatory arthritis: a pilot study

 

All patients (n = 22)

Dieters (n = 15)

Nondieters (n = 7)

Methotrexate (n = 14)

No methotrexate (n = 8)

Age† (years)

50 (44–62)

50 (44–62)

50 (43–62)

53 (44–62)

49 (40–62)

Women (n [%])

17 (77)

12 (80)

5 (71)

12 (86)

5 (62)

Black/Asian/Caucasian/Mixed (n/n/n/n)

1/3/16/2

1/3/11/0

0/0/5/2

0/2/11/1

1/1/5/1

RA/spondyloarthropathy (n/n)

15/7

10/5

5/2

10/4

5/3

Disease duration† (years)

5.5 (0.3–15)

2 (0.25–13)

12 (5–30)*

7 (0.25–15)

5 (0.5–12)

Smoking (n [%])

5 (29)

1 (7)

4 (57)

2 (14)

2 (25)

Alcohol (n [%])

6 (27)

4 (27)

2 (29)

4 (29)

2 (25)

Hypertension (n [%])

10 (45)

6 (40)

5 (57)

9 (64)

1 (13)

Diabetes (n [%])

5 (35)

4 (27)

1 (14)

3 (21)

2 (25)

Antihypertensives (n [%])

7 (41)

7 (47)

0 (0)

6 (42)

1 (13)

Antidiabetics (n [%])

3 (18)

3 (20)

0 (0)

2 (14)

1 (13)

Estrogen (n [%])

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

NSAIDs (n [%])

17 (77)

10 (67)

3 (43)

8 (57)

5 (63)

Prednisone (n [%])

2 (6)

0 (0)

2 (29)

1 (7)

1 (13)

BMI† (kg/m2)

27.6 (24.8–33.5)

28.3 (27.1–35.0)

22.2 (21.9–33.2)

27.7 (24.8–35.0)

27.6 (22.2–33.2)

C-reactive protein† (mg/l)

22 (10–47)

21 (6–39)

36 (18–71)

31 (11–86)

14 (5–47)

Insulin† (μU/ml)

14.9 (10.0–19.3)

14.9 (9.6–19.3)

16 (13.4–20.9)

16.9 (10.2–19.6)

12.8 (9.5–16)

Glucose† (mmol/l)

5.3 (4.9–6.3)

5.4 (5.1–7.6)

5.2 (4.6–5.3)

5.3 (5.1–7.3)

5.2 (4.3–6.3)

HOMA† (μU . mmol/ml . l)

3.33 (2.56–4.44)

3.29 (2.36–4.44)

3.48 (2.56–4.92)

3.51 (2.71–4.92)

3.00 (2.28–3.48)

QUICKI†

0.320 (0.307–0.332)

0.320 (0.307–0.336)

0.318 (0.303–0.332)

0.317 (0.303–0.329)

0.324 (0.318–0.337)

Total cholesterol† (mmol/l)

5.5 (4.7–6.3)

5.6 (4.7–6.5)

5.3 (4.6–6.3)

5.3 (4.7–6.2)

5.8 (3.7–6.8)

LDL-cholesterol† (mmol/l)

3.5 (2.9–4.1)

3.3 (2.9–4.3)

3.7 (3–4.1)

3.2 (2.9–3.8)

3.8 (1.8–5.4)

HDL-cholesterol† (mmol/l)

1.19 (0.93–1.50)

1.10 (0.93–1.50)

1.30 (0.91–1.50)

1.05 (0.81–0.60)

1.25 (1.11–1.52)

Triglycerides† (mmol/l)

1.6 (0.9–2.5)

2.2 (1.1–3.2)

1.1 (0.9–1.6)

1.9 (1.1–3.2)

1.3 (0.8–2.5)

  1. †Results expressed as median (interquartile range). Nondieters were compared with dieters and nonusers of methotrexate with users. *P = 0.045. BMI, body mass index; HDL, high-density lipoprotein; HOMA, Homeostatis Model Assessment for Insulin Resistance; LDL, low-density lipoprotein; NSAID, nonsteroidal anti-inflammatory drug; QUICKI, Quantitative Insulin Sensitivity Check Index; RA, rheumatoid arthritis.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us